| Dr Salem I Elkhayat, MD | |
|
180 W Esplanade Ave, Kenner, LA 70065-2467 | |
| (504) 468-8600 | |
| (504) 464-8538 |
| Full Name | Dr Salem I Elkhayat |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 9 Years |
| Location | 180 W Esplanade Ave, Kenner, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184073165 | NPI | - | NPPES |
| TRN23800 | Other | FL | MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | TRN23800 (Florida) | Secondary |
| 207P00000X | Emergency Medicine | 312700 (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ochsner Clinic Foundation | New orleans, LA | Hospital |
| Ochsner Medical Center-kenner | Kenner, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St. John Emergency Group Llc | 4082641303 | 22 |
| Belle Chasse Emergency Group Llc | 7113140070 | 73 |
| Luling Emergency Group Llc | 8325352636 | 19 |
| Kenner Emergency Group Llc | 8426011230 | 48 |
News Archive
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Although malaria kills some 600,000 African children each year, most cases of the mosquito-borne parasitic disease in children are mild.
NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe's proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.
Meda has acquired exclusive US, Canadian and Japanese rights for the use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals. As part of the agreement, Meda is taking over full responsibility for development and commercialization of the compound. Flupirtine is currently in phase II development for the patented indication fibromyalgia.
› Verified 7 days ago
| Entity Name | Ochsner Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538151428 PECOS PAC ID: 8224933619 Enrollment ID: O20031126000513 |
News Archive
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Although malaria kills some 600,000 African children each year, most cases of the mosquito-borne parasitic disease in children are mild.
NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe's proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.
Meda has acquired exclusive US, Canadian and Japanese rights for the use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals. As part of the agreement, Meda is taking over full responsibility for development and commercialization of the compound. Flupirtine is currently in phase II development for the patented indication fibromyalgia.
› Verified 7 days ago
| Entity Name | Kenner Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013986546 PECOS PAC ID: 8426011230 Enrollment ID: O20041111000475 |
News Archive
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Although malaria kills some 600,000 African children each year, most cases of the mosquito-borne parasitic disease in children are mild.
NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe's proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.
Meda has acquired exclusive US, Canadian and Japanese rights for the use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals. As part of the agreement, Meda is taking over full responsibility for development and commercialization of the compound. Flupirtine is currently in phase II development for the patented indication fibromyalgia.
› Verified 7 days ago
| Entity Name | St. John Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265401509 PECOS PAC ID: 4082641303 Enrollment ID: O20050719000541 |
News Archive
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Although malaria kills some 600,000 African children each year, most cases of the mosquito-borne parasitic disease in children are mild.
NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe's proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.
Meda has acquired exclusive US, Canadian and Japanese rights for the use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals. As part of the agreement, Meda is taking over full responsibility for development and commercialization of the compound. Flupirtine is currently in phase II development for the patented indication fibromyalgia.
› Verified 7 days ago
| Entity Name | Slidell Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295158418 PECOS PAC ID: 1254562663 Enrollment ID: O20140328000931 |
News Archive
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Although malaria kills some 600,000 African children each year, most cases of the mosquito-borne parasitic disease in children are mild.
NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe's proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.
Meda has acquired exclusive US, Canadian and Japanese rights for the use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals. As part of the agreement, Meda is taking over full responsibility for development and commercialization of the compound. Flupirtine is currently in phase II development for the patented indication fibromyalgia.
› Verified 7 days ago
| Entity Name | Belle Chasse Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851714075 PECOS PAC ID: 7113140070 Enrollment ID: O20140521001580 |
News Archive
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Although malaria kills some 600,000 African children each year, most cases of the mosquito-borne parasitic disease in children are mild.
NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe's proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.
Meda has acquired exclusive US, Canadian and Japanese rights for the use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals. As part of the agreement, Meda is taking over full responsibility for development and commercialization of the compound. Flupirtine is currently in phase II development for the patented indication fibromyalgia.
› Verified 7 days ago
| Entity Name | Luling Emergency Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528446101 PECOS PAC ID: 8325352636 Enrollment ID: O20150730013151 |
News Archive
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Although malaria kills some 600,000 African children each year, most cases of the mosquito-borne parasitic disease in children are mild.
NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe's proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.
Meda has acquired exclusive US, Canadian and Japanese rights for the use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals. As part of the agreement, Meda is taking over full responsibility for development and commercialization of the compound. Flupirtine is currently in phase II development for the patented indication fibromyalgia.
› Verified 7 days ago
| Entity Name | Vincent Emergency Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740816917 PECOS PAC ID: 0840621926 Enrollment ID: O20200505000479 |
News Archive
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Although malaria kills some 600,000 African children each year, most cases of the mosquito-borne parasitic disease in children are mild.
NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe's proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.
Meda has acquired exclusive US, Canadian and Japanese rights for the use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals. As part of the agreement, Meda is taking over full responsibility for development and commercialization of the compound. Flupirtine is currently in phase II development for the patented indication fibromyalgia.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Salem I Elkhayat, MD 180 W Esplanade Ave, Kenner, LA 70065-2467 Ph: (504) 468-8600 | Dr Salem I Elkhayat, MD 180 W Esplanade Ave, Kenner, LA 70065-2467 Ph: (504) 468-8600 |
News Archive
Diseases affecting the kidneys represent a major and unsolved health issue worldwide. The kidneys rarely recover function once they are damaged by disease, highlighting the urgent need for better knowledge of kidney development and physiology.
Although malaria kills some 600,000 African children each year, most cases of the mosquito-borne parasitic disease in children are mild.
NuPathe Inc., a specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, today announced data from the pivotal Phase III trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraine. Zelrix combines NuPathe's proprietary SmartRelief™ iontophoretic transdermal technology with sumatriptan, the most prescribed treatment for acute migraine in the United States.
Meda has acquired exclusive US, Canadian and Japanese rights for the use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals. As part of the agreement, Meda is taking over full responsibility for development and commercialization of the compound. Flupirtine is currently in phase II development for the patented indication fibromyalgia.
› Verified 7 days ago
Dr. Vanessa Maria Piazza, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 180 W Esplanade Ave, Kenner, LA 70065 Phone: 504-282-2875 | |
Dr. Michael Rudolf Jegart, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 180 W Esplanade Ave, Kenner, LA 70065 Phone: 985-448-3251 | |
Hanna Kaufman Lurye, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 180 W Esplanade Ave, Kenner, LA 70065 Phone: 504-464-8015 Fax: 504-464-8538 | |
Dr. Michele Campisi, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 180 W Esplanade Ave, Kenner, LA 70065 Phone: 302-227-8508 | |
Dr. Edward Bernard Halton, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4041 Williams Blvd, Suit A9 #234, Kenner, LA 70065 Phone: 504-487-0455 | |
Mario Kakazu, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2552 Williams Blvd, Kenner, LA 70062 Phone: 504-463-3002 |